Vistagen Therapeutics told the FDA about its progress on fasedienol for treating social anxiety disorder.

VTGN · Vistagen Therapeutics, Inc.

The AI's read

That leaves a key question unanswered: what the agency wants before fasedienol can move toward approval. The filing says more studies may be required, and future approval is not assured. Vistagen also says it may not secure enough funding to carry out its plans. With no specific FDA advice or study result in the filing, the update does not clearly change the company's prospects.